Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …

PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated
previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here …

Background Previously reported results from the phase 3 CheckMate 067 trial showed a
significant improvement in objective responses, progression-free survival, and overall …

Background Results from phase 2 and 3 trials in patients with advanced melanoma have
shown significant improvements in the proportion of patients achieving an objective …

Purpose To provide a more precise estimate of long-term survival observed for ipilimumab-
treated patients with advanced melanoma, we performed a pooled analysis of overall …

Objective: Exosomes are nanovesicles that are released from normal and tumor cells and
are detectable in cell culture supernatant and human biological fluids. Although previous …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and
causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts …

Purpose There is evidence from nonrandomized studies that a proportion of ipilimumab-
treated patients with advanced melanoma experience long-term survival. To demonstrate a …

Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …